Stockscreener 앱 받기
6.474
6.59%
-0.426
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas : MoneyGram and Mastercard collaborate to advance digital money movement - MarketScreener
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Yahoo
Arvinas Presents First-in-Human Data For ARV-102 In Neurodegenerative Diseases, Stock Down - Nasdaq
Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener
Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks
Arvinas Presents First-in-Human Data for Investigational - GlobeNewswire
Game-Changing Parkinson's Drug Shows 90% Target Reduction in First Human Trial - Stock Titan
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Yahoo Finance
Edmond DE Rothschild Holding S.A. Takes Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat
BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat
Where are the Opportunities in (ARVN) - news.stocktradersdaily.com
Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India
Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire
Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat
Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat
Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat
Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas chief medical officer sells $74,372 in common stock - Investing.com India
Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com
Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas (NASDAQ:ARVN) Rating Lowered to Neutral at The Goldman Sachs Group - MarketBeat
Arvinas (NASDAQ:ARVN) Given New $32.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Bank of America Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
2.65%
0.06%
자본화:
|
볼륨(24시간):